Company intelligence / Profile preview

Sairopa

Ownership: Private
Development stage: Phase 1

Overview

ADU-1805 (anti-SIRPα antibody) is currently in a first-in-human, open-label, multicenter, multi-arm phase 1 study with patients enrolled across the U.S. and several European countries. Assessments are ongoing in both the ADU-1805 monotherapy and the ADU-1805 plus pembrolizumab dose escalation arms. ADU-1604 (anti-CTLA4 antibody) has recently concluded a phase 1 study for PD-1 relapsed/refractory melanoma.[3]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

ADU-1805

1 more asset in the full pipeline.

Request access →

Partnerships

Exelixis, Inc.

Beyond the preview

Go deeper on Sairopa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sairopa.

Explore the full profile